FibroBiologics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of FibroBiologics (FBLG) with a Buy rating and $12 price target FibroBiologics is a clinical stage biotechnology company focused on development of fibroblast cellular therapies for chronic diseases, the analyst tells investors in a research note. The firm says the company’s “extensive” U.S. and international patent portfolio includes broad potential fibroblast cellular applications that include wound healing, disc degeneration, multiple sclerosis, orthopedics, psoriasis, reversing organ involution, and cancer.